Aligos Receives $25M Upfront Payment, HBV Drug Gets China Breakthrough Designation
ALGS sits 47% above its 52-week low of $4.8 on elevated volume (4.1× avg).
Summary
Aligos Therapeutics received a $25 million upfront payment from its exclusive licensing deal for pevifoscorvir sodium in Greater China. This cash infusion is critical, as the company's Q1 2026 10-Q indicated a 'going concern' warning and a cash runway only into Q4 2026. Additionally, pevifoscorvir sodium was granted Breakthrough Therapy Designation in China, which will accelerate its regulatory review. This news significantly improves the company's financial position and enhances the commercial prospects for its lead HBV drug.
At the time of this announcement, ALGS was trading at $7.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.2M. The 52-week trading range was $4.80 to $13.69. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.